Literature DB >> 29202361

A novel adenine-releasing assay for ribosome-inactivating proteins.

Alexander Weng1.   

Abstract

Ribosome-inactivating proteins (RIPs) are toxic enzymes that are mostly biosynthesized by plants. RIPs are N-glycosidases that cleave an essential adenine molecule from the 28S rRNA. This is followed by the irreversible inhibition of protein synthesis leading to cell death. By fusing RIPs to cancer cell specific targeting ligands RIPs have been utilized for targeted anti-tumor therapy. The anti-tumoral efficiency of such conjugates depends significantly on the N-glycosidase activity of the RIP domain. Different methods have been developed in order to determine the N-glycosidase activity of RIPs and RIP domain containing anti-tumor toxins. However the existing methods are elaborate and include radioassays, HPLC and enzymatic conversion assays. Here, a simple and cost effective N-glycosidase assay is presented, which is based on the direct determination of the released adenine by thin-layer chromatography (TLC) and TLC-densitometry. An adenine based single stranded oligonucleotide is used as substrate. Following TLC development the released adenine is quantified on silica glass plates by UV absorbance at 260nm.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenine release thin-layer chromatography; Ribosome-inactivating protein

Mesh:

Substances:

Year:  2017        PMID: 29202361     DOI: 10.1016/j.jchromb.2017.11.038

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

Review 1.  Dianthin and Its Potential in Targeted Tumor Therapies.

Authors:  Hendrik Fuchs
Journal:  Toxins (Basel)       Date:  2019-10-11       Impact factor: 4.546

2.  Lyophyllin, a Mushroom Protein from the Peptidase M35 Superfamily Is an RNA N-Glycosidase.

Authors:  Jia-Qi Lu; Wei-Wei Shi; Meng-Jie Xiao; Yun-Sang Tang; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

3.  Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861.

Authors:  Hossein Panjideh; Nicole Niesler; Alexander Weng; Hendrik Fuchs
Journal:  Toxins (Basel)       Date:  2022-07-13       Impact factor: 5.075

4.  Sapovaccarin-S1 and -S2, Two Type I RIP Isoforms from the Seeds of Saponaria vaccaria L.

Authors:  Louisa Schlaak; Christoph Weise; Benno Kuropka; Alexander Weng
Journal:  Toxins (Basel)       Date:  2022-06-30       Impact factor: 5.075

5.  An unusual type I ribosome-inactivating protein from Agrostemma githago L.

Authors:  Christoph Weise; Achim Schrot; Leonie T D Wuerger; Jacob Adolf; Roger Gilabert-Oriol; Simko Sama; Matthias F Melzig; Alexander Weng
Journal:  Sci Rep       Date:  2020-09-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.